Menu Search
Equities

Xbrane Biopharma AB

XBRANE:STO

Xbrane Biopharma AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.156
  • Today's Change-0.011 / -6.70%
  • Shares traded7.46m
  • 1 Year change-95.32%
  • Beta1.8910
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in SEK

The 2 analysts offering 12 month price targets for Xbrane Biopharma AB have a median target of 1.28, with a high estimate of 2.27 and a low estimate of 0.300. The median estimate represents a 720.51% increase from the last price of 0.156.
High1,355.1%2.27
Med720.5%1.28
Low92.3%0.300

Earnings history & estimates in SEK

On Aug 28, 2024, Xbrane Biopharma AB reported 2nd quarter 2024 losses of -0.05 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 86.30%.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+25.05%
Xbrane Biopharma AB reported annual 2023 losses of -1.27 per share on Feb 26, 2024.
Average growth rate+0.19%
More ▼

Revenue history & estimates in SEK

Xbrane Biopharma AB (publ) had 2nd quarter 2024 revenues of 52.03m. This missed the 76.00m estimate of the one analyst following the company. This was 15.84% below the prior year's 2nd quarter results.
Average growth rate+54.92%
Xbrane Biopharma AB (publ) had revenues for the full year 2023 of 238.73m. This was 314.33% above the prior year's results.
Average growth rate+104.78%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.